January: TNM001 Phase III Clinical Trial (TNM001-301) achieved enrollment of 1,500 participants.
February: World's First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Drug Sintetol? Officially Approved for Marketing
March: Completed Series C financing.
April: Sintetol? Included in Macao SAR's Catalog of "New Drugs Conditionally Approved for Use by Local Medical Institutions and Application for Registration and Market Launch"
June: Phase III clinical trial results of Siltartoxatug Injection
(Brand Name: Sintetol) were published in the top international
journal "Nature Medicine" (Impact Factor IF=50.0).
September: Successfully passed the dual certification of ISO14001 and ISO45001 international systems
October: Completed B+round financing
October: TNM002 clinical research results invited for on-site presentation at the US/European Emergency Medicine Conference
November: TNM001 enters phase III clinical trial
In June：Trinomab Completed Share Reform and renamed as Zhuhai Trinomab Pharmaceutical Co., Ltd.
In December：A first-in-class anti-tetanus monoclonal antibody TNM002 in the world is filed for NDA.
In March: Trinomab TNM002 obtained breakthrough drug certification;
In November: Trinomab Annunces Initiation of Phase III Clinical Trial for Its Prophylactic Antibody against Tetanus Toxin;
November: Completed approximately 750 million yuan in Series B financing.
In April:the antibody production site in Zhuhai International Health Park was completed and officially put into operation; completed Round A Financing of nearly RMB 450 million.
In August:completed Round A+ Financing of RMB 700 million.
November: The world's first fully human anti-tetanus toxin monoclonal antibody (TNM002), independently developed by our company, entered Phase I clinical trials.
In April: reached a strategic cooperation agreement with WuXi Biologics. In November, entered into a regional license agreement with Changchun BCHT Bio regarding the fully human monoclonal antibody against tetanus toxin.
In September:completed Pre-A round of financing of RMB 200 million.
In May: the fully human monoclonal antibody new drug development center was put into operation.
In September: selected as an Innovation and Entrepreneurship Team in Zhuhai.
On December 17: Trinomab Biotech Co., Ltd was officially registered.
January: TNM001 Phase III Clinical Trial (TNM001-301) achieved enrollment of 1,500 participants.
February: World's First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Drug Sintetol? Officially Approved for Marketing
March: Completed Series C financing.
April: Sintetol? Included in Macao SAR's Catalog of "New Drugs Conditionally Approved for Use by Local Medical Institutions and Application for Registration and Market Launch"
June: Phase III clinical trial results of Siltartoxatug Injection
(Brand Name: Sintetol) were published in the top international
journal "Nature Medicine" (Impact Factor IF=50.0).
September: Successfully passed the dual certification of ISO14001 and ISO45001 international systems
October: Completed B+round financing
October: TNM002 clinical research results invited for on-site presentation at the US/European Emergency Medicine Conference
November: TNM001 enters phase III clinical trial
In June：Trinomab Completed Share Reform and renamed as Zhuhai Trinomab Pharmaceutical Co., Ltd.
In December：A first-in-class anti-tetanus monoclonal antibody TNM002 in the world is filed for NDA.
In March: Trinomab TNM002 obtained breakthrough drug certification;
In November: Trinomab Annunces Initiation of Phase III Clinical Trial for Its Prophylactic Antibody against Tetanus Toxin;
November: Completed approximately 750 million yuan in Series B financing.
In April:the antibody production site in Zhuhai International Health Park was completed and officially put into operation; completed Round A Financing of nearly RMB 450 million.
In August:completed Round A+ Financing of RMB 700 million.
November: The world's first fully human anti-tetanus toxin monoclonal antibody (TNM002), independently developed by our company, entered Phase I clinical trials.
In April: reached a strategic cooperation agreement with WuXi Biologics. In November, entered into a regional license agreement with Changchun BCHT Bio regarding the fully human monoclonal antibody against tetanus toxin.
In September:completed Pre-A round of financing of RMB 200 million.
In May: the fully human monoclonal antibody new drug development center was put into operation.
In September: selected as an Innovation and Entrepreneurship Team in Zhuhai.
On December 17: Trinomab Biotech Co., Ltd was officially registered.
